Should I buy or sell Sangamo Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGMO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGMO, but not buy additional shares or sell existing shares. View SGMO analyst ratings or view top-rated stocks .

What is Sangamo Therapeutics' stock price target for 2024?

7 brokers have issued 1 year price objectives for Sangamo Therapeutics' stock. Their SGMO share price targets range from $1.00 to $10.00. On average, they predict the company's stock price to reach $4.68 in the next twelve months. This suggests a possible upside of 1,093.5% from the stock's current price. View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts .

How have SGMO shares performed in 2023?

Sangamo Therapeutics' stock was trading at $3.14 at the start of the year. Since then, SGMO shares have decreased by 87.5% and is now trading at $0.3917. View the best growth stocks for 2023 here .

When is Sangamo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our SGMO earnings forecast .

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) posted its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.01. The biopharmaceutical company earned $9.40 million during the quarter, compared to analyst estimates of $10.17 million. Sangamo Therapeutics had a negative net margin of 123.88% and a negative trailing twelve-month return on equity of 61.40%.

What ETFs hold Sangamo Therapeutics' stock?

ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) and Morningstar US Small Growth (MSGR) . Global X Genomics & Biotechnology ETF (GNOM) .

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com . Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Micron Technology (MU) , CRISPR Therapeutics (CRSP) , Novavax (NVAX) , Gilead Sciences (GILD) , Brainstorm Cell Therapeutics (BCLI) , Editas Medicine (EDIT) , Netflix (NFLX) and Intel (INTC) .

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (1.65%), Charles Schwab Investment Management Inc. (0.67%), UBS Group AG (0.42%), Mirae Asset Global Investments Co. Ltd. (0.38%), GSA Capital Partners LLP (0.32%) and Jacobs Levy Equity Management Inc. (0.23%). Insiders that own company stock include Biogen Inc, Gary Loeb, John Markels, Rolf Andrew Ramelmeier and Saira Ramasastry. View institutional ownership trends .

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Sangamo Therapeutics Stock Price, News & Analysis (NASDAQ:SGMO)

$0.39

+0.02 (+5.38%)

(As of 11/28/2023 ET)

Compare

Today's Range: $0.36
▼
$0.40
50-Day Range: $0.30
▼
$0.85
52-Week Range: $0.29
▼
$3.76

Volume: 921,835 shs
Average Volume: 2.02 million shs
Market Capitalization: $69.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.68

Sangamo Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.29 Rating Score
Upside/Downside: 1,093.5% Upside
$4.68 Price Target
Short Interest: Healthy
5.81% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.62
Based on 3 Articles This Week
Insider Trading: Selling Shares
$3 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.82) to ($0.53) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

382nd out of 949 stocks

Biological Products, Except Diagnostic Industry

61st out of 161 stocks

3.1

Analyst's Opinion

Consensus Rating
Sangamo Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $4.68, Sangamo Therapeutics has a forecasted upside of 1,093.5% from its current price of $0.39.
Amount of Analyst Coverage
Sangamo Therapeutics has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
5.81% of the outstanding shares of Sangamo Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Sangamo Therapeutics has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Sangamo Therapeutics has recently decreased by 11.04%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Sangamo Therapeutics does not currently pay a dividend.
Dividend Growth
Sangamo Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SGMO.

3.1

News and Social Media Coverage

News Sentiment
Sangamo Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Sangamo Therapeutics this week, compared to 2 articles on an average week.
Search Interest
8 people have searched for SGMO on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
16 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 78% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sangamo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,000,000.00 in company stock.
Percentage Held by Insiders
Only 3.00% of the stock of Sangamo Therapeutics is held by insiders.
Percentage Held by Institutions
59.81% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sangamo Therapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sangamo Therapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sangamo Therapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sangamo Therapeutics Stock (NASDAQ:SGMO)

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

SGMO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SGMO Stock News Headlines

November 26, 2023 | americanbankingnews.com

Sangamo Therapeutics (NASDAQ:SGMO) Receives New Coverage from Analysts at StockNews.com

November 25, 2023 | americanbankingnews.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Rating of "Hold" by Analysts

November 28, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

November 18, 2023 | americanbankingnews.com

Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at StockNews.com

November 8, 2023 | msn.com

Truist Securities Downgrades Sangamo Therapeutics (SGMO)

November 6, 2023 | msn.com

Wells Fargo Downgrades Sangamo Therapeutics (SGMO)

November 6, 2023 | msn.com

Wells Fargo downgrades Sangamo, cites removal of key year-end catalyst

November 6, 2023 | markets.businessinsider.com

Where Sangamo Therapeutics Stands With Analysts

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 6, 2023 | markets.businessinsider.com

What 8 Analyst Ratings Have To Say About Sangamo Therapeutics

November 3, 2023 | msn.com

RBC Capital downgrades Sangamo as biotech moves to save cash

November 3, 2023 | msn.com

RBC Capital Downgrades Sangamo Therapeutics (SGMO)

November 3, 2023 | finance.yahoo.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript

November 3, 2023 | markets.businessinsider.com

What To Know About RBC Capital's Downgrade of Sangamo Therapeutics

November 2, 2023 | msn.com

Biotech company Sangamo Therapeutics laying off 40% of workers, closing HQ

November 2, 2023 | msn.com

Sangamo Therapeutics (SGMO) Price Target Increased by 9.38% to 6.71

November 1, 2023 | finance.yahoo.com

Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results

November 1, 2023 | finance.yahoo.com

Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic Update

November 1, 2023 | markets.businessinsider.com

Sangamo Therapeutics earnings preview: what Wall Street is expecting

October 26, 2023 | finance.yahoo.com

Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

October 25, 2023 | finance.yahoo.com

Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

October 24, 2023 | businesswire.com

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society ...

October 24, 2023 | finance.yahoo.com

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

September 29, 2023 | benzinga.com

Sangamo Therapeutics 10% Owner Sold $3.00M In Company Stock

September 8, 2023 | msn.com

Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction

September 4, 2023 | finance.yahoo.com

Recent uptick might appease Sangamo Therapeutics, Inc. (NASDAQ:SGMO) institutional owners after losing 82% over the past year

September 2, 2023 | finance.yahoo.com

Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases

See More Headlines

Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:SGMO
CUSIP: 80067710
CIK: 1001233
Web: www.sangamo.com
Phone: (510) 970-6000
Fax: 510-236-8951
Employees: 478
Year Founded: 1995

Price Target and Rating

Average Stock Price Target: $4.68
High Stock Price Target: $10.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +1,093.5%
Consensus Rating: Hold
Rating Score (0-4): 2.29
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-192,280,000.00
Net Margins: -123.88%
Pretax Margin: -126.13%
Return on Equity: -61.40%
Return on Assets: -39.63%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.04
Quick Ratio: 3.04

Sales & Book Value

Annual Sales: $111.30 million
Price / Sales: 0.62
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.80 per share
Price / Book: 0.22

Miscellaneous

Outstanding Shares: 177,350,000
Free Float: 172,027,000
Market Cap: $69.47 million
Optionable: Optionable
Beta: 1.12

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Alexander D. Macrae Ch.B (Age 60)
M.B., MRCP, Ph.D., CEO, President & Director
Comp: $1.17M
Ms. Prathyusha Duraibabu CPA (Age 44)
M.B.A., Senior VP, CFO & Principal Accounting Officer
Comp: $628.08k
Mr. D. Mark McClung (Age 60)
Executive VP & COO
Comp: $710.3k
Dr. Jason D. Fontenot Ph.D. (Age 53)
Senior VP & Chief Scientific Officer
Comp: $682.76k
Phillip Ramsey
Head of Technical Operations
Ms. Aron Feingold
Head of Corporate Communications & Investor Relations Officer
Mr. Scott B. Willoughby (Age 48)
Senior VP, General Counsel & Corporate Secretary
Ms. Whitney Jones
Chief People Officer
Dr. Nathalie Dubois-Stringfellow Ph.D. (Age 61)
Senior VP & Chief Development Officer
Dr. Lisa Rojkjaer M.D. (Age 57)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SGMO Stock Analysis - Frequently Asked Questions

Should I buy or sell Sangamo Therapeutics stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGMO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGMO, but not buy additional shares or sell existing shares.
View SGMO analyst ratings or view top-rated stocks.
What is Sangamo Therapeutics' stock price target for 2024?: 7 brokers have issued 1 year price objectives for Sangamo Therapeutics' stock. Their SGMO share price targets range from $1.00 to $10.00. On average, they predict the company's stock price to reach $4.68 in the next twelve months. This suggests a possible upside of 1,093.5% from the stock's current price.
View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts.
How have SGMO shares performed in 2023?: Sangamo Therapeutics' stock was trading at $3.14 at the start of the year. Since then, SGMO shares have decreased by 87.5% and is now trading at $0.3917.
View the best growth stocks for 2023 here.
When is Sangamo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our SGMO earnings forecast.
How were Sangamo Therapeutics' earnings last quarter?: Sangamo Therapeutics, Inc. (NASDAQ:SGMO) posted its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.01. The biopharmaceutical company earned $9.40 million during the quarter, compared to analyst estimates of $10.17 million. Sangamo Therapeutics had a negative net margin of 123.88% and a negative trailing twelve-month return on equity of 61.40%.
What ETFs hold Sangamo Therapeutics' stock?: ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) and Morningstar US Small Growth (MSGR).Global X Genomics & Biotechnology ETF (GNOM).

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?: 10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.
What other stocks do shareholders of Sangamo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).
Who are Sangamo Therapeutics' major shareholders?: Sangamo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (1.65%), Charles Schwab Investment Management Inc. (0.67%), UBS Group AG (0.42%), Mirae Asset Global Investments Co. Ltd. (0.38%), GSA Capital Partners LLP (0.32%) and Jacobs Levy Equity Management Inc. (0.23%). Insiders that own company stock include Biogen Inc, Gary Loeb, John Markels, Rolf Andrew Ramelmeier and Saira Ramasastry.
View institutional ownership trends.
How do I buy shares of Sangamo Therapeutics?: Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SGMO) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial